Abstract 497P
Background
The primary site of colorectal cancer (CRC) influences survival outcomes when metastasized to the liver or lung, with left-sided CRC being associated with longer survival than right-sided CRC. Additionally, the timing of metastasis, whether synchronous or metachronous, has been suggested as a factor for survival, with synchronous metastasis generally considered more aggressive than metachronous CRC with brain metastasis (BM). We investigated the effect of both CRC’s primary location and metastatic timing on overall survival (OS) upon metastasis to the brain.
Methods
We systematically searched PubMed, Embase, and the Cochrane Library. We included studies that described patients diagnosed with BM from CRC, with reports on survival outcomes based on different primary tumor sites (left vs right) or metastatic timing (synchronous vs metachronous). Within the eligible studies, we extracted hazard ratios (HR) for OS and conducted a meta-analysis by using the random-effect model.
Results
Out of 5836 studies identified through our search, 7 studies met the inclusion criteria for the meta-analysis. Similar to lung and liver metastasis of CRC, left-sided primary CRC exhibits better OS than right-sided CRC (multivariate HR = 0.71, 95% CI: 0.54-0.94, univariate HR = 0.75, 95% CI: 0.57-0.99) when metastasized to the brain. Regarding the timing of metastasis, we found no significant difference in OS between synchronous and metachronous metastasis (HR = 0.83, 95% CI: 0.48-1.43). Table: 497P
Hazard ratio of the included studies
Study | HR | 95% CI | |
Right colon vs left colon (reference = right), multivariate analysis | |||
Bergen 2021 | 0.65 | 0.46-0.92 | |
Chen 2022 | 0.94 | 0.56-1.57 | |
Chen 2023 | 0.49 | 0.18-1.34 | |
Total | 0.71 | 0.54-0.94 | I2: 0% |
Right colon vs left colon (reference = right), univariate analysis | |||
Bergen 2021 | 0.63 | 0.44-0.89 | |
Bonadio 2021 | 1.14 | 0.80-1.62 | |
Chen 2022 | 0.74 | 0.48-1.14 | |
Chen 2023 | 0.37 | 0.17-0.81 | |
Michl 2015 | 0.79 | 0.57-1.09 | |
Total | 0.75 | 0.57-0.99 | I2: 58% |
Synchronous vs metachronous (reference = metachronous), univariate analysis | |||
Chen 2023 | 0.83 | 0.44-1.58 | |
Mege 2013 | 0.50 | 0.10-2.60 | |
Tanriverdi 2014 | 1.14 | 0.31-4.13 | |
Total | 0.83 | 0.48-1.43 | I2: 0% |
Abbreviations: HR, hazard ratio; CI, confidence interval
Conclusions
Left-sided colon cancer exhibited higher OS compared to right-sided colon cancer, consistent with findings in lung and liver metastasis. However, OS did not differ between synchronous and metachronous metastasis. Further studies comparing the genotypes and mutations of CRC with BM based on their primary location and metastatic timing are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
596P - Dose-individualisation of fluoropyrimidines in <italic>DPYD</italic> wild-type patients: Final results from the Alpe2U study
Presenter: Niels Heersche
Session: Poster session 16
597P - Hyperthermic intraperitoneal chemotherapy for the management of gastrointestinal cancers: An analysis of the immediate postoperative period
Presenter: Filipa Simões
Session: Poster session 16
598TiP - PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
Presenter: Thomas Aparicio
Session: Poster session 16
599TiP - PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
Presenter: Tomoki Sakakida
Session: Poster session 16
600TiP - A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
Presenter: Maria Elena Elez Fernandez
Session: Poster session 16
601TiP - A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
Presenter: Ilya Pokataev
Session: Poster session 16
602TiP - Radical concurrent chemoradiotherapy with DDP/5-FU and PD-1 antibody for non-metastatic rectal squamous cell carcinoma: A multicenter, prospective, single-arm, phase II study
Presenter: Jun Huang
Session: Poster session 16
454P - Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial
Presenter: Juan Manuel Sepúlveda
Session: Poster session 16
455P - Phase II trial of hippocampus-avoidance whole-brain radiation therapy with simultaneous integrated boost for multiple brain metastases in non-small cell lung cancer
Presenter: Yatian Liu
Session: Poster session 16
456P - Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study
Presenter: Manuel Alejandro Mazariegos-Rubi
Session: Poster session 16